343 related articles for article (PubMed ID: 27429362)
1. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
Furumoto Y; Smith CK; Blanco L; Zhao W; Brooks SR; Thacker SG; Abdalrahman Z; Sciumè G; Tsai WL; Trier AM; Nunez L; Mast L; Hoffmann V; Remaley AT; O'Shea JJ; Kaplan MJ; Gadina M
Arthritis Rheumatol; 2017 Jan; 69(1):148-160. PubMed ID: 27429362
[TBL] [Abstract][Full Text] [Related]
2. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.
Knight JS; Subramanian V; O'Dell AA; Yalavarthi S; Zhao W; Smith CK; Hodgin JB; Thompson PR; Kaplan MJ
Ann Rheum Dis; 2015 Dec; 74(12):2199-206. PubMed ID: 25104775
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor.
Yan Q; Chen W; Song H; Long X; Zhang Z; Tang X; Chen H; Lin H; Sun L
Front Immunol; 2021; 12():675542. PubMed ID: 34394075
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Hasni SA; Gupta S; Davis M; Poncio E; Temesgen-Oyelakin Y; Carlucci PM; Wang X; Naqi M; Playford MP; Goel RR; Li X; Biehl AJ; Ochoa-Navas I; Manna Z; Shi Y; Thomas D; Chen J; Biancotto A; Apps R; Cheung F; Kotliarov Y; Babyak AL; Zhou H; Shi R; Stagliano K; Tsai WL; Vian L; Gazaniga N; Giudice V; Lu S; Brooks SR; MacKay M; Gregersen P; Mehta NN; Remaley AT; Diamond B; O'Shea JJ; Gadina M; Kaplan MJ
Nat Commun; 2021 Jun; 12(1):3391. PubMed ID: 34099646
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.
Chen YL; Liu LX; Huang Q; Li XY; Hong XP; Liu DZ
Front Immunol; 2021; 12():654376. PubMed ID: 33936080
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre.
You H; Zhang G; Wang Q; Zhang S; Zhao J; Tian X; Li H; Li M; Zeng X
Ann Rheum Dis; 2019 Oct; 78(10):1441-1443. PubMed ID: 31005902
[No Abstract] [Full Text] [Related]
7. Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone.
Blanco LP; Pedersen HL; Wang X; Lightfoot YL; Seto N; Carmona-Rivera C; Yu ZX; Hoffmann V; Yuen PST; Kaplan MJ
Arthritis Rheumatol; 2020 Mar; 72(3):454-464. PubMed ID: 31566908
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus.
Reynolds JA; Rosenberg AZ; Smith CK; Sergeant JC; Rice GI; Briggs TA; Bruce IN; Kaplan MJ
Arthritis Rheumatol; 2016 Dec; 68(12):2929-2935. PubMed ID: 27390112
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
10. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
11. Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
Fukuyama T; Ehling S; Wilzopolski J; Bäumer W
BMC Pharmacol Toxicol; 2018 Jul; 19(1):37. PubMed ID: 29970189
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
13. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.
Ikeda K; Hayakawa K; Fujishiro M; Kawasaki M; Hirai T; Tsushima H; Miyashita T; Suzuki S; Morimoto S; Tamura N; Takamori K; Ogawa H; Sekigawa I
BMC Immunol; 2017 Aug; 18(1):41. PubMed ID: 28830352
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-25 is upregulated in patients with systemic lupus erythematosus and ameliorates murine lupus by inhibiting inflammatory cytokine production.
Li Y; Wang R; Liu S; Liu J; Pan W; Li F; Li J; Meng D
Int Immunopharmacol; 2019 Sep; 74():105680. PubMed ID: 31200339
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
18. The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.
Wang H; Feng X; Han P; Lei Y; Xia Y; Tian D; Yan W
Mol Med Rep; 2019 Dec; 20(6):4883-4892. PubMed ID: 31638166
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
Nishimura K; Saegusa J; Matsuki F; Akashi K; Kageyama G; Morinobu A
Arthritis Rheumatol; 2015 Apr; 67(4):893-902. PubMed ID: 25545152
[TBL] [Abstract][Full Text] [Related]
20. Polydatin effectively attenuates disease activity in lupus-prone mouse models by blocking ROS-mediated NET formation.
Liao P; He Y; Yang F; Luo G; Zhuang J; Zhai Z; Zhuang L; Lin Z; Zheng J; Sun E
Arthritis Res Ther; 2018 Nov; 20(1):254. PubMed ID: 30419963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
